Company news

EyePoint, Inc. news in 2026

EyePoint, Inc.'s news releases, calls and decks from 2026, newest first.

View company

EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026

November 5, 2026

EyePoint Announces Strategic Prioritization

October 19, 2026

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

October 19, 2026

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

September 2, 2026

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

August 5, 2026

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

July 30, 2026

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

July 13, 2026

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

May 13, 2026

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

May 6, 2026

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

April 29, 2026

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

March 3, 2026

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

March 1, 2026

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

February 24, 2026

EyePoint Appoints Michael Campbell as Chief Commercial Officer

February 18, 2026

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

January 15, 2026

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

January 6, 2026

Calls in 2026

Decks in 2026